



July 2016 Corporate Presentation

DAVID P. SOUTHWELL, *President and CEO*
Cantor Fitzgerald 2nd Annual Health Care Conference

Forward Looking Statements

This presentation contains forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

In some cases, you can identify forward-looking statements by terminology such as "may," "might," "could," "would," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "target," "potential," "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those

The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, we may elect to update these forward-looking statements at any time. In the future, we have no current intention of doing so except as required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

All trademarks and registered trademarks are the property of their respective owners.

Trabodenoson is an investigational compound and is not approved by the FDA for any indication.

Inotek: Transforming Glaucoma Treatment

Trabodenoson: Novel adenosine mimetic that stimulates a natural pathway

• **Glaucoma:** *\$5.6 billion worldwide market with low compliance.¹

1

Phase 1 Monotherapy showed **no dose related side effects** (ocular or systemic) at greater than Phase 3 doses

2

Phase 2 Monotherapy showed **clear dose response**, good ocular and systemic safety, ability to dose QD or BID, additive efficacy to prostaglandins

3

First Phase 3 M... MATrX-1, tests... doses against p... Results 4Q'16

First fixed-dose combination trial to initiate in 2016 | Adenosine A₁ activation is neuroprotective in the r

Leadership with History Together

David P. Southwell, MBA
President & CEO

Rudolf Baumgartner, M.D.
Chief Medical Officer

William McVicar, Ph.D.
Chief Scientific Officer

Claudine Prowse, Ph.D.
VP Strategy

Cadn M.I.
VP C Med

\$2 Billion U.S. Glaucoma Market

Unmet Need: Effective QD treatment with minimal side effects

GLAUCOMA PRESCRIPTION MARKET SHARE

First Line:


Prostaglandin Analogs

Monotherapy QD Dosing

IOP Drop from Baseline: 6–8 mmHg*

Ocular Side Effects

- Red eye (hyperemia)
- Iris discoloration
- Blurred vision
- Darkening of the eyelids
- Adipose tissue shrinkage



Second Line:

Adjunctive Agents

Monotherapy BID or QD

Ocular and Systemic Side Effects

- Severe respiratory reactions
- Blurred vision
- Allergic conjunctivitis
- Itching (pruritus), lacrimation

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.